<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>SweetDeep: A Wearable AI Solution for Real-Time Non-Invasive Diabetes Screening - Health AI Hub</title>
    <meta name="description" content="SweetDeep introduces a compact neural network for real-time, non-invasive type 2 diabetes screening leveraging physiological and demographic data from Samsung G">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>SweetDeep: A Wearable AI Solution for Real-Time Non-Invasive Diabetes Screening</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.03471v1" target="_blank">2512.03471v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-03
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Ian Henriques, Lynda Elhassar, Sarvesh Relekar, Denis Walrave, Shayan Hassantabar, Vishu Ghanakota, Adel Laoui, Mahmoud Aich, Rafia Tir, Mohamed Zerguine, Samir Louafi, Moncef Kimouche, Emmanuel Cosson, Niraj K Jha
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, cs.CY
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.03471v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.03471v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">SweetDeep introduces a compact neural network for real-time, non-invasive type 2 diabetes screening leveraging physiological and demographic data from Samsung Galaxy Watch 7 devices. Collected from 285 participants in free-living conditions, the AI solution achieved 82.5% patient-level accuracy, demonstrating a scalable and cost-effective approach to early diabetes detection.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research provides a significant step towards accessible, non-invasive diabetes screening, potentially enabling earlier diagnosis and intervention for millions globally. This could mitigate severe health complications associated with undiagnosed or late-stage type 2 diabetes and reduce healthcare burdens.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>SweetDeep is a compact neural network (an AI model) designed to process physiological and demographic data collected from consumer wearables (Samsung Galaxy Watch 7) to detect type 2 diabetes. It serves as a real-time, non-invasive screening tool, offering an alternative to traditional biochemical assays for disease detection and diagnosis.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the global need for scalable, cost-effective, and non-invasive screening methods for type 2 diabetes, replacing current invasive biochemical assays.</li>
                    
                    <li>Utilizes a compact neural network named SweetDeep, comprising fewer than 3,000 parameters, trained on engineered physiological and demographic features.</li>
                    
                    <li>Data was collected from 285 diabetic and non-diabetic participants across EU and MENA regions using Samsung Galaxy Watch 7 devices over six days in real-world, free-living conditions.</li>
                    
                    <li>Achieved 82.5% patient-level accuracy, with an 82.1% macro-F1 score, 79.7% sensitivity, and 84.6% specificity under three-fold cross-validation.</li>
                    
                    <li>Performance improved to 84.5% accuracy on remaining patients when allowing the model to abstain on less than 10% of low-confidence predictions.</li>
                    
                    <li>Demonstrates the efficacy of combining engineered features with lightweight AI architectures for accurate, rapid, and generalizable detection in real-world wearable settings.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study involved collecting physiological and demographic data from 285 participants (diabetic and non-diabetic) in EU and MENA regions over six days, using Samsung Galaxy Watch 7 devices in free-living conditions. Each participant contributed approximately 20 two-minute sensor recordings daily. A compact neural network, SweetDeep (under 3,000 parameters), was trained on engineered features from this dataset and evaluated using three-fold cross-validation.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>SweetDeep achieved a patient-level accuracy of 82.5% for type 2 diabetes screening, with a macro-F1 score of 82.1%, sensitivity of 79.7%, and specificity of 84.6%. The expected calibration error was 5.5%. Allowing the model to abstain on less than 10% of low-confidence predictions boosted accuracy to 84.5% on the remaining patient population.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>SweetDeep offers a novel pathway for widespread, convenient, and cost-effective real-time non-invasive screening for type 2 diabetes. This could revolutionize early detection efforts, facilitating proactive health management, reducing diagnostic delays, and potentially lowering the incidence of severe diabetes-related complications, thereby easing the burden on healthcare systems.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>While demonstrating promise, the study's dataset size of 285 participants, though geographically diverse, might require expansion for broader demographic representation and validation across varied populations. The reliance on a specific wearable device (Samsung Galaxy Watch 7) may limit direct generalizability to other platforms. The details of the 'engineered features' are not elaborated, which could impact reproducibility and deeper physiological understanding.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future research should focus on further validating and expanding the model's generalizability across larger and more diverse populations, potentially including evaluation on different wearable devices. Detailed investigation and publication of the specific engineered features could enhance transparency and facilitate clinical adoption. Longitudinal studies are also crucial to assess the long-term efficacy and impact of this real-time screening solution.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Endocrinology</span>
                    
                    <span class="tag">Preventive Medicine</span>
                    
                    <span class="tag">Primary Care</span>
                    
                    <span class="tag">Public Health</span>
                    
                    <span class="tag">Digital Health</span>
                    
                    <span class="tag">Cardiometabolic Health</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Diabetes screening</span>
                    
                    <span class="tag tag-keyword">Wearable AI</span>
                    
                    <span class="tag tag-keyword">Non-invasive diagnosis</span>
                    
                    <span class="tag tag-keyword">Type 2 diabetes</span>
                    
                    <span class="tag tag-keyword">Machine learning</span>
                    
                    <span class="tag tag-keyword">Physiological data</span>
                    
                    <span class="tag tag-keyword">Neural networks</span>
                    
                    <span class="tag tag-keyword">Digital health</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">The global rise in type 2 diabetes underscores the need for scalable and cost-effective screening methods. Current diagnosis requires biochemical assays, which are invasive and costly. Advances in consumer wearables have enabled early explorations of machine learning-based disease detection, but prior studies were limited to controlled settings. We present SweetDeep, a compact neural network trained on physiological and demographic data from 285 (diabetic and non-diabetic) participants in the EU and MENA regions, collected using Samsung Galaxy Watch 7 devices in free-living conditions over six days. Each participant contributed multiple 2-minute sensor recordings per day, totaling approximately 20 recordings per individual. Despite comprising fewer than 3,000 parameters, SweetDeep achieves 82.5% patient-level accuracy (82.1% macro-F1, 79.7% sensitivity, 84.6% specificity) under three-fold cross-validation, with an expected calibration error of 5.5%. Allowing the model to abstain on less than 10% of low-confidence patient predictions yields an accuracy of 84.5% on the remaining patients. These findings demonstrate that combining engineered features with lightweight architectures can support accurate, rapid, and generalizable detection of type 2 diabetes in real-world wearable settings.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>12 pages, 6 figures. Submitted to the IEEE Journal of Biomedical and Health Informatics</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>